-
Benzinga's 2024 Virtual Healthcare Summit: What's Next In Health?
Tuesday, March 19, 2024 - 4:52pm | 840Circle March 20 on your calendars! Starting at 10:25 a.m. EST Wednesday, the Benzinga Virtual Healthcare Summit 2024 is the place to be. Imagine a digital room buzzing with the likes of Beachbody’s Mark Goldston, Autonomix Medical’s Lori Bisson, and IGC Pharma’s Ram Mukunda (NYSE:...
-
Wednesdays With Wedbush: Analyst Laura Chico On The State Of Biotech
Wednesday, December 29, 2021 - 3:30pm | 689For most issues in the biotech sector, it was a rough 2021, especially when compared to the gains in the S&P 500 index, Wedbush's Laura Chico said Wednesday on "PreMarket Prep Plus." Chico, the senior vice president of biotech equity research at the analyst firm, said she...
-
Millendo's Lead Asset Could Address Unmet PWS Need, Wedbush Says
Friday, July 19, 2019 - 3:53pm | 251Millendo Therapeutics Inc’s (NASDAQ: MLND) lead asset livoletide is in a registrational study (ZEPHYR) for the treatment of PraderWilli Syndrome (PWS), which is an unmet need, according to Wedbush. The Analyst Wedbush’s Laura Chico initiated coverage of Millendo Therapeutics with an...
-
Analysts Initiate Bullish Coverage Of Prevail Therapeutics
Monday, July 15, 2019 - 2:01pm | 528Prevail Therapeutics Inc (NASDAQ: PRVL) shares traded higher on Monday after a pair of Wall Street analyst initiated bullish coverage of the stock. The Analyst Bank of America analyst Tazeen Ahmad initiated coverage of Prevail with a Buy rating and $15 price target. The Thesis Ahmad said Prevail...
-
Wedbush Remains Bullish On Acer Therapeutics, Says Edsivo Review Appears On Track
Monday, June 10, 2019 - 3:23pm | 407Wedbush's meetings with Acer Therapeutics Inc (NASDAQ: ACER) in the wake of last week's 14-percent decline in the stock suggest that the review of ast week’s 14 percent decline in the company’s share price, suggest the review of the company's Edsivo product is on track...
-
Acorda's Prospects Remain Dubious Despite Inbrija Approval, Says Bearish Raymond James
Wednesday, December 26, 2018 - 10:45am | 444Acorda Therapeutics Inc (NASDAQ: ACOR) announced FDA approval for its Parkinson's drug Inbrija Monday, boosting the stock in premarket trading. Not everyone is sold on the product’s prospects. The Analyst Raymond James analyst Laura Chico maintained an Underperform rating on the...
-
Why Raymond James Is Bullish On Deciphera, Dova Pharmaceuticals
Wednesday, August 29, 2018 - 2:19pm | 652Raymond James launched coverage of two pharmaceutical names Tuesday afternoon with bullish ratings. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) is a clinical-stage biopharmaceutical company that addresses key mechanisms of tumor drug resistance. Dova Pharmaceuticals Inc (NASDAQ: DOVA)...
-
After Biogen's Alzheimer's Update, Wall Street Reacts
Friday, July 6, 2018 - 1:27pm | 643Biogen Inc (NASDAQ: BIIB) and its Japanese partner Eisai disclosed encouraging results from an 18-month Phase 2 study of its Alzheimer's therapy BAN2401. Here's how some Street analysts reacted to the news. The Analysts Raymond James' Laura Chico maintained a Market...